| Cardiac Ischemia and Reperfusion | Lifetime | 175 | TH 1 | 98.63 |
| Hemoglobinopathies and Related Disorders | Lifetime | 261 | TH 2 | 98.23 |
| Trace Elements in Health | Lifetime | 286 | TH 1 | 98.01 |
| Iron Metabolism and Disorders | Lifetime | 338 | TH 3 | 97.76 |
| Cardiac electrophysiology and arrhythmias | Lifetime | 873 | TH 2 | 98.05 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 140 | TH 1 | 96.73 |
| GDF15 and Related Biomarkers | Lifetime | 73 | TH 1 | 94.69 |
| Diabetes Treatment and Management | Lifetime | 888 | TH 1 | 97.06 |
| Biochemical effects in animals | Lifetime | 886 | TH 3 | 95.05 |
| Fibroblast Growth Factor Research | Lifetime | 487 | TH 1 | 94.00 |
| Kruppel-like factors research | Lifetime | 453 | TH 1 | 92.16 |
| Vagus Nerve Stimulation Research | Lifetime | 245 | TH 1 | 92.29 |
| Antioxidants, Aging, Portulaca oleracea | Lifetime | 37 | TH 1 | 89.24 |
| Cancer-related cognitive impairment studies | Lifetime | 461 | TH 2 | 91.16 |
| Hydrogen's biological and therapeutic effects | Lifetime | 234 | TH 1 | 87.72 |
| Heart rate and cardiovascular health | Lifetime | 568 | TH 2 | 73.02 |
| Cardiac Ischemia and Reperfusion | 2021-2025 | 2 | TH 1 | 98.42 |
| Mitochondrial Function and Pathology | 2021-2025 | 19 | TH 2 | 98.90 |
| Chemotherapy-induced cardiotoxicity and mitigation | 2021-2025 | 12 | TH 1 | 98.66 |
| Cancer-related cognitive impairment studies | 2021-2025 | 47 | TH 1 | 94.61 |
| Iron Metabolism and Disorders | 2021-2025 | 211 | TH 4 | 92.75 |
| Trace Elements in Health | 2021-2025 | 171 | TH 1 | 90.90 |
| Biochemical effects in animals | 2021-2025 | 153 | TH 2 | 89.99 |
| Hemoglobinopathies and Related Disorders | 2021-2025 | 417 | TH 8 | 91.63 |
| Neuroinflammation and Neurodegeneration Mechanisms | 2021-2025 | 814 | TH 4 | 89.93 |
| Metabolism and Genetic Disorders | 2021-2025 | 315 | TH 2 | 88.94 |
| Adipose Tissue and Metabolism | 2021-2025 | 763 | TH 1 | 88.55 |
| Vagus Nerve Stimulation Research | 2021-2025 | 94 | TH 1 | 88.05 |
| Cancer Treatment and Pharmacology | 2021-2025 | 529 | TH 2 | 90.14 |
| Cardiac electrophysiology and arrhythmias | 2021-2025 | 953 | TH 3 | 89.44 |
| Inflammasome and immune disorders | 2021-2025 | 695 | TH 1 | 84.78 |
| Electron Spin Resonance Studies | 2021-2025 | 173 | TH 3 | 85.60 |
| Anesthesia and Neurotoxicity Research | 2021-2025 | 423 | TH 3 | 82.50 |
| Cardiac Fibrosis and Remodeling | 2021-2025 | 290 | TH 4 | 80.26 |
| Nicotinic Acetylcholine Receptors Study | 2021-2025 | 217 | TH 1 | 79.84 |
| Clostridium difficile and Clostridium perfringens research | 2021-2025 | 853 | TH 10 | 79.57 |
| Antioxidants, Aging, Portulaca oleracea | 2021-2025 | 26 | TH 3 | 74.78 |
| Immune Response and Inflammation | 2021-2025 | 994 | TH 7 | 73.86 |
| Signaling Pathways in Disease | 2021-2025 | 230 | TH 1 | 71.29 |
| Hydrogen's biological and therapeutic effects | 2021-2025 | 120 | TH 1 | 76.89 |
| Heart rate and cardiovascular health | 2021-2025 | 70 | TH 1 | 67.31 |
| Fibroblast Growth Factor Research | 2021-2025 | 667 | TH 4 | 63.32 |
| GDF15 and Related Biomarkers | 2021-2025 | 433 | TH 1 | 61.52 |
| NF-κB Signaling Pathways | 2021-2025 | 740 | TH 2 | 37.59 |
| Synthesis of heterocyclic compounds | 2021-2025 | 574 | TH 1 | 27.53 |
